

Nordic Precision Medicine Forum

20-21 March 2018, Copenhagen



@precisionforum #nordicpmf

Programme

Sponsors:



**FOUNDATION
MEDICINE®**



BLUEBEE

Partners:



**BIO
PEOPLE**

Denmark's Life Science Cluster



Creating Opportunities



**MEDICON
VILLAGE**



**OSLO CANCER
CLUSTER**

www.precisionmedicineforum.com

20th March 2018 Programme

12.30

Registration and welcome coffee

13.15

Opening remarks from the Chair: **Vivienne Parry OBE**, Head of Engagement at Genomics England

A scientist by training, Vivienne hosts medical programmes for Radio 4, writes widely on health, presents films, facilitates many high level conferences and debates and trains young researchers. She also has a part time role as head of engagement at Genomics England which is delivering the 100,000 Genomes Project. In September 2017 she was appointed to the board of UK Research & Innovation.

13.20

Nationwide Precision Medicine Initiatives; an Update on Current Plans and Where we are Heading

A series of presentations outlining precision medicine based initiatives across the Nordics. Discover the latest progress and what the future holds for precision medicine. From the latest about genomics centres to bio-banking and data sharing. Followed by a panel session allowing more in-depth discussions.

Gert Sørensen, Director, Danish National Genome Centre

Nordic biobank initiatives: example FinnGen

Aarno Palotie, Research Director, FIMM

Richard Rosenquist Brandell, Professor of Clinical Genetics Department of Molecular Medicine and Surgery, Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital. Project Leader, Genomics Medicine Sweden

Personalizing in Finland

Dr. Jaakko Yrjö-Koskinen, Special Advisor, Health Affairs, Department of Social and Health Services Ministerial Counsellor

The Norwegian Strategy for Personalised. Medicine in Healthcare

- Brief overview of the main areas covered by the strategy

- Update on ongoing actions to implement the strategy and what the Directorate of health has done so far
- Highlights from our “insight” survey among the public and relevant health personnel groups
- Perspectives for 2018

Anne Forus, Senior Adviser, Department of Biotechnology and Health Legislation, Norwegian Health Directorate

Nordic Alliance for Sequencing and Personalized Medicine

Stephen McAdam Healthcare Director, DNV GL Digital Solutions

15.15

Networking coffee

15.50

The Patients Perspective:

In 2017 Lars Werner was appointed member of the Board responsible for Implementing the National Strategy for Precision Medicine in Denmark by “Danske Patienter” (Danish Patients), an umbrella organisation for a number of patient organisations in Denmark. This presentation will discuss patient centric precision medicine and how patient groups are working together with all other stakeholders to help devise the best route to precision medicine across Denmark.

Lars Werner, Director, Psoriasisforeningen

The Person in Personalized Medicine: Ethical and Societal Challenges

- The economy of anticipation: How promissory futures colonize the present
- Ethics on the ground in labs, clinics, and among patients and the public
- Societal challenges related to incidental findings, patient engagement, and public legitimacy

Prof. Mette Nordahl Svendsen, Department of Public Health Centre for Medical Science and Technology Studies, University of Copenhagen

16.50

How Biomarker Development and Diagnostics are key to Precision Medicine

The need for thinking in composite biomarkers and to ensure we have freedom to operate with the purpose of epidemiological investigations to understand the underlying disease biology. This will lead to new disease classes - a discussion of how to validate diagnoses will be needed.

Birgitte Søgaard, Divisional Director Clinical & Quantitative Pharmacology, H. Lundbeck A/S

Investigating the opportunities for establishing a biomarker development infrastructure in Denmark. Kim will discuss his efforts within a Government funded project focusing on evaluating the development of biomarkers as an emerging growth area in Denmark.

Kim Holmstrøm, R&D Manager Molecular Detection, Bioneer A/S

NEW CONCEPTS IN DISEASE CLASSIFICATION – “BLOOD ON THE TRACKS”

Toward prediction of drug specific resistance to standard drugs in relapsed B cell malignancies

Hans Erik Johnsen, Clinical Professor in Hematology, Aalborg University

The use of Next Generation Sequencing (NGS) in pathology

Precision medicine takes into account individual variability in genes, environment, and lifestyle for each person. This approach allows prediction of treatment strategies of cancer patients. It is in contrast to a one-size-fits-all approach, and therefore the extent of analyses is grown to fulfill the aim of the optimal analytical answer for the patient.

The clinical demand for mutation detection within multiple genes from a single tumor sample requires molecular diagnostic laboratories to develop rapid, high-throughput, highly sensitive, accurate and parallel testing within tight budget constraints. To meet this demand, we implemented Next Generation

Sequencing (NGS). As NGS opens the possibility for more extensive tumor profiling, this increases the opportunities for patients to access different drugs both in routine diagnostic setting but also in experimental diagnostic setting. The presentation gives an overview of the analyses performed in the laboratory.

Estrid Høgdall, Clinical professor in Molecular Pathology at University of Copenhagen and Head of Molecular Unit, Department of Pathology

18.20

Complimentary Networking Dinner and Drinks Reception (Everest Ballroom Foyer)



21st March 2018 Programme

8.20
Welcome Coffee

8.45
Welcome introduction from your Chair:

8.50
Interview session with Precision Medicine thought leaders:

This unique session sees an open discussion allowing for a vibrant discussion of the most pressing issues facing us in the implementation of precision medicine. Including a diverse range of topics from the convergence of multi-omics to lifestyle, cross border collaboration and overcoming challenges such as regulatory hurdles.

Olli Kallioniemi, Professor at Karolinska Institutet and Director of SciLifeLab

Paul W Franks Professor and Deputy Director of Lund University Diabetes Center in Sweden, Head of Genetic & Molecular Epidemiology Unit

Bogi Eliassen, Health Futurist, Copenhagen Institute for Futures Studies

9.40
Clinical Implementation of Precision Medicine
Precision Medicine can Radically Improve Healthcare within the Next Decade:

- How Precision Medicine can reduce the use and cost of ineffective drugs
- New technical solutions to bridge the gap between DNA and diagnosis
- Single cell analysis
- Practical solutions for clinical translation

Mikael Benson, MD, Professor, The Center for Personalised Medicine, Linköping University Hospital

Overview of Norwegian clinical trial (MetAction study) where we have looked for a defined set of actionable targets in metastatic solid tumors (by sequencing) and leveraged treatment on an individual basis:

Gunhild M. Mælandsmo, Prof, PhD, Head, Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital
Precision Medicine in Early Clinical Cancer Trials

Ulrik Lassen, Head of Unit Oncology, Rigshospitalet

10.45
Networking Coffee Break

11.15
Data, Data Everywhere- How do we best standardize, regulate and utilize the enormous amount of data we have?

The role of RWE in evidence generation

Danilo Verge, Vice President for CV, Renal and Metabolism; Global Medical Affairs, AstraZeneca

Precision Medicine: A data enabled reality

Hans Cobben, CEO, Bluebee

Regulated and unregulated data – how to get the most from both worlds

- Digital Health Hub from Finland – a one-stop-shop for regulated well-being data
- Market share of regulated health data compared to unregulated has started to decrease
- Unregulated data sits in silos and is hard to reach for researchers
- How to utilize data from decentralized services and create incentives for sharing

Markus Kalliola, Specialist, Sitra

Patient-past Based Precision Medicine

Soren Brunak, Professor, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen

12.30
Data models for dynamic precision medicine

Martin Bøgsted, professor in bioinformatics and statistics, Department of Clinical Medicine, Aalborg University and Department of Haematology, Aalborg University Hospital

12.50
Networking Lunch

13.50
Focus on Disease areas

Whilst cancer leads the way precision medicine is high on the agenda for rare diseases, diabetes, cardio and more. Hear about the latest breakthroughs and progress that is being made across disease:

Oncology:

NGS - applications in oncology. Cases where we have used NGS-based comprehensive genomic profiling on oncology patients. Johann will present and discuss what could be done with the results of such testing.

Johan Hartman, MD, PhD, Associate Professor in Pathology, Dept of Oncology-Pathology, Karolinska Institutet and University Laboratory

A new subclassification of type 2 diabetes-steps towards precision medicine:

Leif will discuss the clinical consequences of a new subclassification of Type 2 diabetes (Ahlqvist E et al. Novel subgroups of adult-onset diabetes and their association with outcome: a data-driven cluster analysis of six variables. Lancet Diabetes & Endocrinology, March 2, 2018. This new substratification might eventually help to tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes.

Leif Groop, Senior Professor at Lund University, Sweden and Research Director at Institute of Molecular Medicine Finland (FIMM)

Prognostic Biomarkers Associated with Cardiovascular Events in Atrial Fibrillation

Agneta Siegbahn, Professor Uppsala University, SciLifeLab

14.50
Transcriptome wide analysis in situ - a potential tool for precision medicine

Prof Joakim Lundeberg, Director of the Genomics Platform, Science for Life Laboratory KTH Division of Gene Technology

15.10
Networking Coffee

15.40
Roundtable Sessions:

Designed to allow participants to deep-delve into specific topics, this session promotes open debate and helps formulate new strategies and partnerships.

Clinical Implementation of Precision Medicine

Tarec Christoffer El-Galaly, Consultant Haematologist, Aalborg University Hospital & Associate Professor at Aalborg University.

Bound to co-exist: Population genomics and precision medicine?

Hans Cobben, CEO, BlueBee

BLUEBEE

AI/Machine Learning

Anne Mette Bang, Customer Engagement Manager, Cambio Healthcare Systems



Big Data

Bogi Eliassen, Health Futurist, Copenhagen Institute for Futures Studies

Alleviating bottlenecks in Clinical Implementation of Precision Medicine

Bobbie Ray-Sannerud, Program Director, Life Sciences research unit of DNV GL

Vibeke Binz Vallevik, Principal Researcher at the Life Sciences research unit of DNV GL

Biobanking

Lasse Boding, PhD, Coordinator, Danish National Biobank, Biobank and Biomarkers, Statens Serum Institut

Precision Oncology

Nils Brüner, MD, DMSc, Co-founder and Chairman of the Board, of Scandion Oncology A/S. Professor University of Copenhagen

17.00
Closing Remarks